Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

Bibliographic Details
Main Authors: Johnson, Barbara H., Bonafede, Machaon M., Watson, Crystal
Format: Online
Language:English
Published: Springer International Publishing 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513191/
id pubmed-4513191
recordtype oai_dc
spelling pubmed-45131912015-07-24 Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients Johnson, Barbara H. Bonafede, Machaon M. Watson, Crystal Original Research Article Springer International Publishing 2015-06-26 2015 /pmc/articles/PMC4513191/ /pubmed/26113055 http://dx.doi.org/10.1007/s40263-015-0251-1 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Johnson, Barbara H.
Bonafede, Machaon M.
Watson, Crystal
spellingShingle Johnson, Barbara H.
Bonafede, Machaon M.
Watson, Crystal
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
author_facet Johnson, Barbara H.
Bonafede, Machaon M.
Watson, Crystal
author_sort Johnson, Barbara H.
title Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
title_short Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
title_full Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
title_fullStr Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
title_full_unstemmed Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
title_sort platform therapy compared with natalizumab for multiple sclerosis: relapse rates and time to relapse among propensity score-matched us patients
description
publisher Springer International Publishing
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513191/
_version_ 1613251530728669184

Similar Items